Start with chronic lymphocytic leukemia, then reuse UniProt P78527 as the stable protein anchor across project notes and exports.
CHEMBL3142 Target Snapshot
DNA-dependent protein kinase catalytic subunit · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13DNA-dependent protein kinase catalytic subunit shows clinical signal disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P78527. Start with chronic lymphocytic leukemia, then reuse UniProt P78527 as the stable protein anchor across project notes and exports.
DNA-dependent protein kinase catalytic subunit shows clinical signal disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with chronic lymphocytic leukemia because it currently carries clinical signal support. Linked drugs include CC-115. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDNA-dependent protein kinase catalytic subunit
Review this target as DNA-dependent protein kinase catalytic subunit, mapped to UniProt P78527. Sequence length is 4128 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats DNA-dependent protein kinase catalytic subunit as ChEMBL target CHEMBL3142, mapped to UniProt P78527. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether DNA-dependent protein kinase catalytic subunit is the right protein anchor across sources, using UniProt P78527 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic lymphocytic leukemia is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | DNA-dependent protein kinase catalytic subunit |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P78527 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | DNA-dependent protein kinase catalytic subunit |
| UniProt Accession | P78527 |
| Component Type | Protein |
| Sequence Length | 4128 aa |
DNA-dependent protein kinase catalytic subunit
How to read this target
Review this target as DNA-dependent protein kinase catalytic subunit, mapped to UniProt P78527. Sequence length is 4128 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
DNA-dependent protein kinase catalytic subunit shows clinical signal disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with chronic lymphocytic leukemia because it currently carries clinical signal support. Linked drugs include CC-115. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4447991 | 10.1 | IC50 | 0.07943 | Preclinical |
| CHEMBL5563688 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5566630 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5570653 | 9.96 | IC50 | 0.11 | Preclinical |
| CHEMBL5180090 | 9.92 | IC50 | 0.12 | Preclinical |
| CHEMBL5194436 | 9.89 | IC50 | 0.13 | Preclinical |
| CHEMBL6065576 | 9.8 | IC50 | 0.158 | Preclinical |
| CHEMBL5890243 | 9.8 | IC50 | 0.158 | Preclinical |
| CHEMBL4560221 | 9.8 | IC50 | 0.158 | Preclinical |
| CHEMBL4450232 | 9.7 | IC50 | 0.1995 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 325 assays, 1,455 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 201 | 1,262 | 7.2 |
| cell-based format | 86 | 179 | 6.3 |
| subcellular format | 28 | 4 | 7.2 |
| assay format | 10 | 10 | 7.4 |